ClinicalTrials.gg
CompletedNCT00112294Updated Dec 24, 2015Results posted

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

A Phase 3 interventional study of Paclitaxel (Taxane) and Docetaxel (Taxane) in Non-Small-Cell Lung Carcinoma, sponsored by Eli Lilly and Company. Completed at 125 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-24.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
755
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 2 under way, none of them phase 3. Cetuximab · Carcinoma, Non-Small-Cell Lung.

Enrollment
3rd of 51
755 · median 63
Started
2004
with 7 others
Phase 3
5 of 52
none open now
Registered
10th of 52
by date
Lead sponsor
13 of 52
Eli Lilly and Company

Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment of the 51 interventional ones that give a count, is one of 8 that started in 2004, is one of 5 in phase 3, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with Taxane/Carboplatin (T/C) alone. The safety of this treatment will also be studied.

03

Conditions studied

  • Non-Small-Cell Lung Carcinoma

Keywords

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have advanced or non-small cell lung cancer that has not been previously treated with any chemotherapy.
  • Tumor/disease lesions that can be measured bidimensionally.
  • Must be able to carry-out work of light or sedentary nature (e.g. light house work, office work).
  • Adequate recovery from recent surgery or radiation therapy.
  • Must be at least 4 weeks from last major surgery or prior treatment with an agent. At least 12 weeks from any radiation therapy to chest.
  • Accessible for treatment, follow-up and required visits at a participating center(s).

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy or chemotherapy for the treatment of lung cancer.
  • Prior treatment with cetuximab or other epidermal growth factor (EGFR)-targeted therapy.
  • Prior severe infusion reaction to antibody therapy.
  • Concurrent (previous malignancy without evidence of disease for 5 years will be allowed to enter trial).
  • Concurrent chemotherapy or therapy with another agent not indicated in the protocol.
  • Serious uncontrolled medical disorders that would impair the ability to receive therapy.
  • History of myocardial infarction within prior 3 months, uncontrolled angina, uncontrolled arrhythmia, or uncontrolled congestive heart failure.
  • Symptomatic or uncontrolled in the central nervous system. Subjects receiving a for central nervous system (CNS) metastases are not eligible, but those receiving an anticonvulsant are eligible.
  • Peripheral neuropathy >= grade 2 (Common Toxicity Criteria Adverse Event [] Version 3.0).
  • Inadequate hematologic and/or liver and/or kidney function.
  • Sexually active and fertile individuals or partners of these individuals who are unwilling or unable to use an acceptable method of for entire trial and up to 4 weeks after the study.
  • Women who are pregnant or breastfeeding.
  • Women with a positive pregnancy test on enrollment prior to study drug administration.
  • Altered mental status or psychiatric condition that prohibits understanding or rendering of consent.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
755 participants (actual)

Study arms

  • Active comparator
    Cetuximab+Taxane+Carboplatin (C/T/C)

    Cetuximab was administered at an initial dose (Week 1) of 400 mg/m\^2 intravenous (IV) infusion (infused over 120 minutes) and a weekly maintenance dose of 250 mg/m\^2 IV infusion (infused over 60 minutes). A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m\^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m\^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.

    Drug: Paclitaxel (Taxane) · Drug: Docetaxel (Taxane) · Drug: Carboplatin · Drug: Cetuximab

  • Active comparator
    Taxane+Carboplatin (T/C)

    A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m\^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m\^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.

    Drug: Paclitaxel (Taxane) · Drug: Docetaxel (Taxane) · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Median Number of Months of Progression-free Survival (PFS)

    Interval between randomization date \& earliest date of disease progression/death due to any cause, assessed by the Independent Radiology Review Committee (IRRC) using modified World Health Organization (WHO) criteria to define progressive disease (PD): \>=25% increase in sum of products of diameters (SOPD) of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion. If no progression/death, date of last tumor assessment used. For participants who had no on-study tumor assessments \& were still alive, date of randomization used.

    Time frame: From randomization to evidence of disease progression/death or date of last tumor assessment (up to 26 months).

Secondary outcomes

  1. Number of Participants With Complete Response (CR) or Partial Response (PR)

    Tumor response was defined as the number of participants whose best response was CR or PR, per the IRRC assessment, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR: \>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression. To qualify as CR or PR, no new lesions could be present.

    Time frame: From randomization to end of study drug therapy (up to 174 weeks).

  2. Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD)

    Disease control was defined as the number of participants whose best response was CR, PR, or SD, per the IRRC assessment, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR:\>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression (to qualify as CR or PR, no new lesions could be present); SD: participants who did not meet the criteria for CR, PR, or PD (PD:\>=25% increase in SOPD of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion).

    Time frame: From randomization to end of study drug therapy (up to 174 weeks).

  3. Median Number of Months of Response

    Median number of months of response (time from first occurrence of CR/PR to date of PD/death, \[per IRRC assessment,using modified WHO criteria\]) calculated for participants whose best response=CR/PR.For participants who did not progress/die, date of last tumor assessment used.CR:disappearance of all index/non-index lesions;PR:\>= 50% reduction in SOPD of index lesions compared with baseline, no evidence of progression.No new lesions present.PD:\>=25% increase in SOPD of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion.

    Time frame: Time from first occurrence of CR or PR (whichever was recorded first) to the date of PD, death or date of last tumor assessment (up to 19 months).

  4. Median Number of Months to Response

    The median number of months to response was calculated for participants whose best response was CR or PR. It was defined as the time from the first dose of study therapy to the first date that criteria for PR or CR (whichever occurred first)were met. Response was assessed by the IRRC, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR: \>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression. To qualify as CR or PR, no new lesions could be present.

    Time frame: Time from first dose of study therapy to the date of PR or CR, whichever occurred first (up to 13 months).

  5. Median Number of Months of Survival

    The median number of months of survival was defined as the time from randomization to the date of death. For participants who did not die, the date of last contact was used.

    Time frame: From randomization to death or date of last contact (up to 41 months).

  6. Number of Participants With Improvement of Symptoms

    Symptoms were assessed using the Functional Assessment of Cancer Therapy - Lung Cancer Subscale (FACT-LCS) questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic in all symptoms assessed) to 28 (symptom-free on all symptoms assessed). Symptom response (improvement) was defined as \>= 2-point increase from baseline in score (maintained for 2 consecutive assessments, at least 3 weeks apart). Participants with a baseline score of \>= 27 were not evaluable, as it would not have been possible to show an improvement. Participants with no baseline data were also not evaluable.

    Time frame: From randomization to evidence of disease progression/death or date of last symptom assessment (up to 33 weeks).

  7. Median Number of Months Until Symptomatic Progression (Worsening of Symptoms)

    Symptoms were assessed using the FACT-LCS questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic) to 28 (symptom-free). Symptomatic progression was defined as \>= 2-point decrease from baseline in score (maintained for 2 consecutive assessments at least 3 weeks apart). Time to symptomatic progression was defined as the time from randomization to date of symptoms worsening. For participants with no symptom progression, the date of the last symptom assessment was used. See also Outcome Measure 15.

    Time frame: From randomization to evidence of disease progression/death or date of last symptom assessment (up to 33 weeks).

  8. Number of Participants Who Died, or Experienced Other Serious Adverse Events (SAEs) and Adverse Events (AEs)

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). An SAE was defined as an AE that resulted in death, was life-threatening, required hospitalization (or prolongation of existing hospitalization), or was an important medical event.

    Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).

  9. Number of Participants Experiencing AEs Leading to Study Drug Discontinuation

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). The results presented are stratified according to which drug was discontinued.

    Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).

  10. Number of Participants Experiencing Other Significant AEs: Acneform Rash

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term "acneform rash" were of particular importance. These AEs were: rash, rash pustular, rash erythematous, dermatitis acneiform, dermatitis exfoliative, rash papular, rash pruritic, rash generalised, rash macular, rash maculo-papular, acne, acne pustular, skin desquamation and dry skin.

    Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).

  11. Number of Participants Experiencing Other Significant AEs: Infusion Reaction

    AE=any new untoward medical occurrence or worsening of pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term "infusion reaction" were of particular importance. These AEs were: infusion-related reaction, hypersensitivity, anaphylactic reaction, anaphylactic shock, and anaphylactoid reaction regardless of when they occurred. The terms dyspnea, pyrexia and chills were also grouped under infusion reaction, provided the onset date of these toxicities occurred on the first day of study treatment.

    Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).

  12. Number of Participants Experiencing Other Significant AEs: Cardiac AEs

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term "cardiac AE" were of particular importance. These AEs, coded as preferred or other level Medical Dictionary for Regulatory Activities \[MedDRA\] terms were: coronary artery disorders, cardiac arrhythmias, heart failures not elsewhere classified, left ventricular failures, sudden cardiac death, cardiac death and sudden death.

    Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).

  13. Number of Participants Who Exprienced the Most Frequent Grade 3-4 Hematology Abnormalities Occurring in >=5% Participants

    Abnormalities were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC), version 3.0. The scale is graded from 1 (least severe) to 4 (life threatening). Grade 3 and 4 criteria are defined as follows: Neutropenia: Grade 3, neutrophils \<1.0 - 0.5 x 10\^9/L; Grade 4, \<0.5 x 10\^9/L. Leukopenia: Grade 3, leukocytes \<2.0 - 1.0 x 10\^9/L; Grade 4, \<1.0 x 10\^9/L. Thrombocytopenia: Grade 3, platelets \<50.0 - 25.0 x 10\^9/L; Grade 4, \<25.0 x 10\^9/L. Anemia: Grade 3, hemoglobin \<4.9 - 4.0 millimoles (mmol)/L, Grade 4, \<4.0 mmol/L.

    Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).

  14. Number of Participants Who Experienced the Most Frequent Grade 3-4 Serum Chemistry Abnormalities Occurring in >=5% Participants

    Abnormalities were graded according to the NCI CTC, version 3.0. The scale is graded from 1 (least severe) to 4 (life threatening). Grade 3 and 4 criteria are defined as follows: Hyperglycemia (non-fasting): Grade 3, serum glucose \>13.9 - 27.8 mmol/L; Grade 4 \>27.8 mmol/L or acidosis. Hypomagnesemia: Grade 3, serum magnesium \>1.23 - 3.30 mmol/L; Grade 4 \>3.30 mmol/L. Hyponatremia: Grade 3, serum sodium \<130 - 120 mmol/L; Grade 4 \<120 mmol/L. Low albumin: Grade 3, serum albumin \<20 g/L; Grade 4 not applicable.

    Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).

  15. Number of Participants Who Had Unscheduled Visits to Physicians, Clinics, Hospitals and Other Unscheduled Major Medicinal Procedures

    Participants were to complete log to collect information on unscheduled visits to physicians,clinics,hospitals \& other unscheduled major procedures.If asked, participants were to complete and return log to site upon routinely scheduled visits.The purpose of this exploratory analysis was to understand the economical implications as a secondary objective.This was not a pivotal study \& therefore not needed to support any arguments with regulatory authorities concerning cost-benefit,hence,it was not necessary to conduct this analysis. There is no intent on conducting this analysis in the future.

    Time frame: Day 1 of each cycle of treatment, at the end of study therapy evaluation and at the first follow-up visit (6 weeks after the end of study therapy evaluation).

Other outcomes

  1. Median Change From Baseline in Symptoms, by Time Point

    Symptoms were assessed using the FACT-LCS questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic) to 28 (symptom-free). The median change from baseline score was calculated at 3-weekly intervals. See also Outcome Measure 8.

    Time frame: From randomization to evidence of disease progression/death or date of last symptom assessment (up to 33 weeks).

07

Results

Posted Oct 5, 2010

Participant flow

Participant flow — Overall Study
MilestoneCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Started325320
Never treated1318
Completed320320
Not completed50
Withdrew: Still on study50

Outcome measures

PrimaryMedian Number of Months of Progression-free Survival (PFS)

Interval between randomization date \& earliest date of disease progression/death due to any cause, assessed by the Independent Radiology Review Committee (IRRC) using modified World Health Organization (WHO) criteria to define progressive disease (PD): \>=25% increase in sum of products of diameters (SOPD) of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion. If no progression/death, date of last tumor assessment used. For participants who had no on-study tumor assessments \& were still alive, date of randomization used.

Time frame:
From randomization to evidence of disease progression/death or date of last tumor assessment (up to 26 months).
Reported as:
Median · Months
Median Number of Months of Progression-free Survival (PFS)
MonthsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Median Number of Months of Progression-free Survival (PFS)4.40 (4.11 to 5.06)4.24 (3.94 to 4.63)
Statistical analysis
  • Cetuximab+Taxane+Carboplatin (C/T/C) vs Taxane+Carboplatin (T/C) · Log Rank · p = 0.2358 (Since only 1 primary comparison was conducted, no adjustment for multiple comparisons was needed.) · Hazard ratio (hr): 0.902 · 95% CI 0.761 to 1.069The hazard ratio of C/T/C to T/C was estimated by means of a stratified Cox's proportional hazard model, with treatment as the single covariate.
SecondaryNumber of Participants With Complete Response (CR) or Partial Response (PR)

Tumor response was defined as the number of participants whose best response was CR or PR, per the IRRC assessment, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR: \>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression. To qualify as CR or PR, no new lesions could be present.

Time frame:
From randomization to end of study drug therapy (up to 174 weeks).
Reported as:
Number · Participants
Number of Participants With Complete Response (CR) or Partial Response (PR)
ParticipantsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Number of Participants With Complete Response (CR) or Partial Response (PR)8758
Statistical analysis
  • Cetuximab+Taxane+Carboplatin (C/T/C) vs Taxane+Carboplatin (T/C) · Cochran-Mantel-Haenszel · p = 0.0066 · Odds ratio (or): 1.675 · 95% CI 1.152 to 2.436The odds ratio is presented for C/T/C to T/C.
SecondaryNumber of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD)

Disease control was defined as the number of participants whose best response was CR, PR, or SD, per the IRRC assessment, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR:\>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression (to qualify as CR or PR, no new lesions could be present); SD: participants who did not meet the criteria for CR, PR, or PD (PD:\>=25% increase in SOPD of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion).

Time frame:
From randomization to end of study drug therapy (up to 174 weeks).
Reported as:
Number · Participants
Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD)
ParticipantsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD)230212
Statistical analysis
  • Cetuximab+Taxane+Carboplatin (C/T/C) vs Taxane+Carboplatin (T/C) · Cochran-Mantel-Haenszel · p = 0.1501 · Odds ratio (or): 1.265 · 95% CI 0.918 to 1.741The odds ratio is presented for C/T/C to T/C.
SecondaryMedian Number of Months of Response

Median number of months of response (time from first occurrence of CR/PR to date of PD/death, \[per IRRC assessment,using modified WHO criteria\]) calculated for participants whose best response=CR/PR.For participants who did not progress/die, date of last tumor assessment used.CR:disappearance of all index/non-index lesions;PR:\>= 50% reduction in SOPD of index lesions compared with baseline, no evidence of progression.No new lesions present.PD:\>=25% increase in SOPD of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion.

Time frame:
Time from first occurrence of CR or PR (whichever was recorded first) to the date of PD, death or date of last tumor assessment (up to 19 months).
Reported as:
Median · Months
Median Number of Months of Response
MonthsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Median Number of Months of Response5.55 (4.40 to 6.83)4.90 (4.24 to 5.72)
SecondaryMedian Number of Months to Response

The median number of months to response was calculated for participants whose best response was CR or PR. It was defined as the time from the first dose of study therapy to the first date that criteria for PR or CR (whichever occurred first)were met. Response was assessed by the IRRC, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR: \>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression. To qualify as CR or PR, no new lesions could be present.

Time frame:
Time from first dose of study therapy to the date of PR or CR, whichever occurred first (up to 13 months).
Reported as:
Median · Months
Median Number of Months to Response
MonthsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Median Number of Months to Response1.38 (1.08 to 12.65)1.35 (0.99 to 4.83)
SecondaryMedian Number of Months of Survival

The median number of months of survival was defined as the time from randomization to the date of death. For participants who did not die, the date of last contact was used.

Time frame:
From randomization to death or date of last contact (up to 41 months).
Reported as:
Median · Months
Median Number of Months of Survival
MonthsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Median Number of Months of Survival9.69 (8.28 to 11.50)8.38 (7.33 to 9.92)
Statistical analysis
  • Cetuximab+Taxane+Carboplatin (C/T/C) vs Taxane+Carboplatin (T/C) · Log Rank · p = 0.1685 (An interim analysis on survival was performed. Final p-value was adjusted using an alpha spending function. At the interim analysis (data not reported here) the type 1 error was 0.0001, and the rest is for the final look.) · Hazard ratio (hr): 0.890 · 95% CI 0.754 to 1.051The hazard ratio of C/T/C to T/C was estimated by means of a stratified Cox's proportional hazard model with treatment as the single covariate.
SecondaryNumber of Participants With Improvement of Symptoms

Symptoms were assessed using the Functional Assessment of Cancer Therapy - Lung Cancer Subscale (FACT-LCS) questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic in all symptoms assessed) to 28 (symptom-free on all symptoms assessed). Symptom response (improvement) was defined as \>= 2-point increase from baseline in score (maintained for 2 consecutive assessments, at least 3 weeks apart). Participants with a baseline score of \>= 27 were not evaluable, as it would not have been possible to show an improvement. Participants with no baseline data were also not evaluable.

Time frame:
From randomization to evidence of disease progression/death or date of last symptom assessment (up to 33 weeks).
Reported as:
Number · Participants
Number of Participants With Improvement of Symptoms
ParticipantsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Number of Participants With Improvement of Symptoms10792
Statistical analysis
  • Cetuximab+Taxane+Carboplatin (C/T/C) vs Taxane+Carboplatin (T/C) · Cochran-Mantel-Haenszel · p = 0.26
SecondaryMedian Number of Months Until Symptomatic Progression (Worsening of Symptoms)

Symptoms were assessed using the FACT-LCS questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic) to 28 (symptom-free). Symptomatic progression was defined as \>= 2-point decrease from baseline in score (maintained for 2 consecutive assessments at least 3 weeks apart). Time to symptomatic progression was defined as the time from randomization to date of symptoms worsening. For participants with no symptom progression, the date of the last symptom assessment was used. See also Outcome Measure 15.

Time frame:
From randomization to evidence of disease progression/death or date of last symptom assessment (up to 33 weeks).

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Died, or Experienced Other Serious Adverse Events (SAEs) and Adverse Events (AEs)

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). An SAE was defined as an AE that resulted in death, was life-threatening, required hospitalization (or prolongation of existing hospitalization), or was an important medical event.

Time frame:
From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Reported as:
Number · Participants
Number of Participants Who Died, or Experienced Other Serious Adverse Events (SAEs) and Adverse Events (AEs)
ParticipantsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Death3827
Serious adverse events183121
Adverse events324320
SecondaryNumber of Participants Experiencing AEs Leading to Study Drug Discontinuation

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). The results presented are stratified according to which drug was discontinued.

Time frame:
From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Reported as:
Number · participants
Number of Participants Experiencing AEs Leading to Study Drug Discontinuation
participantsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Cetuximab1000
Taxane8054
Carboplatin7852
SecondaryNumber of Participants Experiencing Other Significant AEs: Acneform Rash

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term "acneform rash" were of particular importance. These AEs were: rash, rash pustular, rash erythematous, dermatitis acneiform, dermatitis exfoliative, rash papular, rash pruritic, rash generalised, rash macular, rash maculo-papular, acne, acne pustular, skin desquamation and dry skin.

Time frame:
From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Reported as:
Number · Participants
Number of Participants Experiencing Other Significant AEs: Acneform Rash
ParticipantsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Number of Participants Experiencing Other Significant AEs: Acneform Rash24656
SecondaryNumber of Participants Experiencing Other Significant AEs: Infusion Reaction

AE=any new untoward medical occurrence or worsening of pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term "infusion reaction" were of particular importance. These AEs were: infusion-related reaction, hypersensitivity, anaphylactic reaction, anaphylactic shock, and anaphylactoid reaction regardless of when they occurred. The terms dyspnea, pyrexia and chills were also grouped under infusion reaction, provided the onset date of these toxicities occurred on the first day of study treatment.

Time frame:
From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Reported as:
Number · Participants
Number of Participants Experiencing Other Significant AEs: Infusion Reaction
ParticipantsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Number of Participants Experiencing Other Significant AEs: Infusion Reaction4518
SecondaryNumber of Participants Experiencing Other Significant AEs: Cardiac AEs

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term "cardiac AE" were of particular importance. These AEs, coded as preferred or other level Medical Dictionary for Regulatory Activities \[MedDRA\] terms were: coronary artery disorders, cardiac arrhythmias, heart failures not elsewhere classified, left ventricular failures, sudden cardiac death, cardiac death and sudden death.

Time frame:
From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Reported as:
Number · Participants
Number of Participants Experiencing Other Significant AEs: Cardiac AEs
ParticipantsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Number of Participants Experiencing Other Significant AEs: Cardiac AEs5825
SecondaryNumber of Participants Who Exprienced the Most Frequent Grade 3-4 Hematology Abnormalities Occurring in >=5% Participants

Abnormalities were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC), version 3.0. The scale is graded from 1 (least severe) to 4 (life threatening). Grade 3 and 4 criteria are defined as follows: Neutropenia: Grade 3, neutrophils \<1.0 - 0.5 x 10\^9/L; Grade 4, \<0.5 x 10\^9/L. Leukopenia: Grade 3, leukocytes \<2.0 - 1.0 x 10\^9/L; Grade 4, \<1.0 x 10\^9/L. Thrombocytopenia: Grade 3, platelets \<50.0 - 25.0 x 10\^9/L; Grade 4, \<25.0 x 10\^9/L. Anemia: Grade 3, hemoglobin \<4.9 - 4.0 millimoles (mmol)/L, Grade 4, \<4.0 mmol/L.

Time frame:
From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Reported as:
Number · Participants
Number of Participants Who Exprienced the Most Frequent Grade 3-4 Hematology Abnormalities Occurring in >=5% Participants
ParticipantsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Neutropenia198177
Leukopenia13997
Thrombocytopenia3329
Anemia1715
Other pre-specifiedMedian Change From Baseline in Symptoms, by Time Point

Symptoms were assessed using the FACT-LCS questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic) to 28 (symptom-free). The median change from baseline score was calculated at 3-weekly intervals. See also Outcome Measure 8.

Time frame:
From randomization to evidence of disease progression/death or date of last symptom assessment (up to 33 weeks).
Reported as:
Median · Units on a scale
Median Change From Baseline in Symptoms, by Time Point
Units on a scaleCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
3 weeks (n = 286, 257)1.0 (-1.0 to 3.0)0.8 (-2.0 to 3.0)
6 weeks (n = 254, 221)1.0 (-2.0 to 4.0)1.0 (-2.0 to 4.0)
9 weeks (n = 203, 175)1.0 (-2.0 to 4.0)1.0 (-2.0 to 4.0)
12 weeks (n = 178, 161)1.0 (-2.0 to 4.0)0.0 (-2.0 to 4.0)
15 weeks (n = 155, 121)1.0 (-2.0 to 4.0)1.0 (-2.0 to 5.0)
18 weeks (n = 126, 91)1.0 (-1.0 to 4.0)2.0 (-2.0 to 5.0)
21 weeks (n = 96, 43)2.0 (-1.0 to 4.0)3.0 (-1.0 to 7.0)
24 weeks (n = 90, 41)2.0 (-2.0 to 5.0)1.0 (-1.0 to 5.0)
27 weeks (n = 60, 22)3.0 (-1.0 to 5.0)3.5 (-1.0 to 7.0)
30 weeks (n = 56, 15)1.5 (-1.0 to 5.0)3.0 (0.0 to 5.0)
33 weeks (n = 43, 7)2.1 (-1.0 to 6.0)3.0 (-1.0 to 8.0)
SecondaryNumber of Participants Who Experienced the Most Frequent Grade 3-4 Serum Chemistry Abnormalities Occurring in >=5% Participants

Abnormalities were graded according to the NCI CTC, version 3.0. The scale is graded from 1 (least severe) to 4 (life threatening). Grade 3 and 4 criteria are defined as follows: Hyperglycemia (non-fasting): Grade 3, serum glucose \>13.9 - 27.8 mmol/L; Grade 4 \>27.8 mmol/L or acidosis. Hypomagnesemia: Grade 3, serum magnesium \>1.23 - 3.30 mmol/L; Grade 4 \>3.30 mmol/L. Hyponatremia: Grade 3, serum sodium \<130 - 120 mmol/L; Grade 4 \<120 mmol/L. Low albumin: Grade 3, serum albumin \<20 g/L; Grade 4 not applicable.

Time frame:
From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Reported as:
Number · Participants
Number of Participants Who Experienced the Most Frequent Grade 3-4 Serum Chemistry Abnormalities Occurring in >=5% Participants
ParticipantsCetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)
Hyperglycemia (non-fasting)3336
Hypomagnesemia262
Hyponatremia2521
Low albumin179
SecondaryNumber of Participants Who Had Unscheduled Visits to Physicians, Clinics, Hospitals and Other Unscheduled Major Medicinal Procedures

Participants were to complete log to collect information on unscheduled visits to physicians,clinics,hospitals \& other unscheduled major procedures.If asked, participants were to complete and return log to site upon routinely scheduled visits.The purpose of this exploratory analysis was to understand the economical implications as a secondary objective.This was not a pivotal study \& therefore not needed to support any arguments with regulatory authorities concerning cost-benefit,hence,it was not necessary to conduct this analysis. There is no intent on conducting this analysis in the future.

Time frame:
Day 1 of each cycle of treatment, at the end of study therapy evaluation and at the first follow-up visit (6 weeks after the end of study therapy evaluation).

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab+Taxane+Carboplatin—183/325 (56.3%)322/325 (99.1%)
Taxane+Carboplatin—121/320 (37.8%)317/320 (99.1%)
Most frequent serious events
Showing 10 of 169
Most frequent serious events
EventCetuximab+Taxane+CarboplatinTaxane+Carboplatin
DehydrationMetabolism and nutrition disorders24/32511/320
PneumoniaInfections and infestations18/32511/320
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)15/32511/320
Febrile neutropeniaBlood and lymphatic system disorders14/3258/320
HypersensitivityImmune system disorders11/3251/320
DyspnoeaRespiratory, thoracic and mediastinal disorders10/3258/320
Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)9/3254/320
NeutropeniaBlood and lymphatic system disorders9/3254/320
Pleural effusionRespiratory, thoracic and mediastinal disorders9/3257/320
Pulmonary embolismRespiratory, thoracic and mediastinal disorders8/3254/320
Most frequent other events
Showing 10 of 61
Most frequent other events
EventCetuximab+Taxane+CarboplatinTaxane+Carboplatin
FatigueGeneral disorders243/325228/320
NauseaGastrointestinal disorders198/325161/320
RashSkin and subcutaneous tissue disorders186/32547/320
DiarrhoeaGastrointestinal disorders156/325105/320
ConstipationGastrointestinal disorders147/32599/320
AlopeciaSkin and subcutaneous tissue disorders118/325141/320
AnorexiaMetabolism and nutrition disorders131/32597/320
VomitingGastrointestinal disorders107/32593/320
DyspnoeaRespiratory, thoracic and mediastinal disorders106/325104/320
CoughRespiratory, thoracic and mediastinal disorders100/32581/320

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)Total
Mean64.0 ± 10.063.9 ± 10.364.0 ± 10.2
Age, Customized
Age, Customized(participants)Cetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)Total
<65 years171165336
>= 65 years167173340
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)Total
Female146134280
Male192204396
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)Total
Asian61016
Black252449
White296300596
Other race11415
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)(Participants)Cetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)Total
0=fully active110114224
1=restricted physically strenuous activity221220441
2=ambulatory but unable to work426
3=capable of only limited self care011
4=completely disabled000
5=dead000
Missing314
Weight
Weight(kg)Cetuximab+Taxane+Carboplatin (C/T/C)Taxane+Carboplatin (T/C)Total
Mean75.0 ± 17.175.3 ± 18.175.1 ± 17.6
08

Study locations

125 sites
  • Local Institution
    Birmingham, Alabama, United States
  • Local Institution
    Mobile, Alabama, United States
  • Local Institution
    Anchorage, Alaska, United States
  • Local Institution
    Tucson, Arizona, United States
  • Local Institution
    Springdale, Arkansas, United States
  • Local Institution
    Anaheim, California, United States
  • Local Institution
    Bakersfield, California, United States
  • Local Institution
    Concord, California, United States
  • Local Institution
    Fountain Valley, California, United States
  • Local Institution
    Gilroy, California, United States
  • Local Institution
    Long Beach, California, United States
  • Local Institution
    Los Angeles, California, United States
  • Local Institution
    Montebello, California, United States
  • Local Institution
    Oxnard, California, United States
  • Local Institution
    Rancho Mirage, California, United States
  • Local Institution
    San Diego, California, United States
  • Local Institution
    Stockton, California, United States
  • Local Institution
    Vista, California, United States
  • Local Institution
    Lakewood, Colorado, United States
  • Local Institution
    Binghamton, Connecticut, United States
  • Local Institution
    Hartford, Connecticut, United States
  • Local Institution
    New London, Connecticut, United States
  • Local Institution
    Norwich, Connecticut, United States
  • Local Institution
    Stamford, Connecticut, United States
  • Local Institution
    Waterbury, Connecticut, United States
  • Local Institution
    Washington, District of Columbia, United States
  • Local Institution
    Boca Raton, Florida, United States
  • Local Institution
    Boynton Beach, Florida, United States
  • Local Institution
    Fort Lauderdale, Florida, United States
  • Local Institution
    Fort Myers, Florida, United States
  • Local Institution
    Inverness, Florida, United States
  • Local Institution
    Jacksonville, Florida, United States
  • Local Institution
    Lakeland, Florida, United States
  • Local Institution
    Lecanto, Florida, United States
  • Local Institution
    Pembroke Pines, Florida, United States
  • Local Institution
    Port Saint Lucie, Florida, United States
  • Local Institution
    Tamarac, Florida, United States
  • Local Institution
    Tampa, Florida, United States
  • Local Institution
    Augusta, Georgia, United States
  • Local Institution
    Columbus, Georgia, United States
  • Local Institution
    Marietta, Georgia, United States
  • Local Institution
    Honolulu, Hawaii, United States
  • Local Institution
    Evanston, Illinois, United States
  • Local Institution
    Joliet, Illinois, United States
  • Local Institution
    Naperville, Illinois, United States
  • Local Institution
    Normal, Illinois, United States
  • Local Institution
    Skokie, Illinois, United States
  • Local Institution
    Fort Wayne, Indiana, United States
  • Local Institution
    Muncie, Indiana, United States
  • Local Institution
    New Albany, Indiana, United States
  • Local Institution
    Terre Haute, Indiana, United States
  • Local Institution
    Vincennes, Indiana, United States
  • Local Institution
    Wichita, Kansas, United States
  • Local Institution
    Hazard, Kentucky, United States
  • Local Institution
    Paducah, Kentucky, United States
  • Local Institution
    Annapolis, Maryland, United States
  • Local Institution
    Baltimore, Maryland, United States
  • Local Institution
    Westminster, Maryland, United States
  • Local Institution
    Boston, Massachusetts, United States
  • Local Institution
    Brockton, Massachusetts, United States
  • Local Institution
    Flint, Michigan, United States
  • Local Institution
    Free Soil, Michigan, United States
  • Local Institution
    Grand Rapids, Michigan, United States
  • Local Institution
    Jackson, Michigan, United States
  • Local Institution
    Dulluth, Minnesota, United States
  • Local Institution
    Minneapolis, Minnesota, United States
  • Local Institution
    St. Louis Park, Minnesota, United States
  • Local Institution
    Jackson, Mississippi, United States
  • Local Institution
    Columbia, Missouri, United States
  • Local Institution
    Jefferson City, Missouri, United States
  • Local Institution
    Dover, New Hampshire, United States
  • Local Institution
    Newark, New Jersey, United States
  • Local Institution
    Bronx, New York, United States
  • Local Institution
    Cooperstown, New York, United States
  • Local Institution
    New City, New York, United States
  • Local Institution
    New Rochelle, New York, United States
  • Local Institution
    Northport, New York, United States
  • Local Institution
    Rochester, New York, United States
  • Local Institution
    Valhalla, New York, United States
  • Local Institution
    Burlington, North Carolina, United States
  • Local Institution
    Charlotte, North Carolina, United States
  • Local Institution
    Gastonia, North Carolina, United States
  • Local Institution
    Greensboro, North Carolina, United States
  • Local Institution
    Greenville, North Carolina, United States
  • Local Institution
    Hickory, North Carolina, United States
  • Local Institution
    Morganton, North Carolina, United States
  • Local Institution
    Wilmington, North Carolina, United States
  • Local Institution
    Winston-Salem, North Carolina, United States
  • Local Institution
    Bismarck, North Dakota, United States
  • Local Institution
    Bismark, North Dakota, United States
  • Local Institution
    Canton, Ohio, United States
  • Local Institution
    Cincinnati, Ohio, United States
  • Local Institution
    Cleveland, Ohio, United States
  • Local Institution
    Columbus, Ohio, United States
  • Local Institution
    Dayton, Ohio, United States
  • Local Institution
    Oklahoma City, Oklahoma, United States
  • Local Institution
    Bethlehem, Pennsylvania, United States
  • Local Institution
    Dunmore, Pennsylvania, United States
  • Local Institution
    Harrisburg, Pennsylvania, United States
  • Local Institution
    Philadelphia, Pennsylvania, United States

Showing the first 100 of 125 sites. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Apr 2007 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2005
First posted
Jun 2, 2005
Start
Dec 2004
Primary completionActual
Apr 2007
CompletionActual
Aug 2008
Results first posted
Oct 5, 2010
Last update
Dec 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00112294
Responsible party
Sponsor
First posted
Jun 2, 2005
Start date
Dec 2004
Primary completion
Apr 2007
Completion
Aug 2008
Results posted
Oct 5, 2010
Last update
Dec 24, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion